Press release
Spinal Muscular Atrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in Spinal Muscular Atrophy Research. Learn more about our innovative pipeline today! @ Spinal Muscular Atrophy Pipeline Outlook [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Spinal Muscular Atrophy Pipeline Report
* In October 2024:- Hoffmann-La Roche- This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with SMA.
* In October 2024:- Lantu Biopharma- Study duration per participant is approximately 25 months including an approximately 30-day screening/baseline period, an approximately 24-month study observation period including 1 treatment day, and an approximately 24-month follow-up period. Patients will be tested at baseline and return for follow-up visits twice a week through the first month post dose, and followed by visits at months 2, 3, 6 12, 18 and 24 post infusion. Unscheduled visits may occur if the investigator determines that they are necessary.
* In October 2024:- Genentech Inc.- A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi Registered U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.
* DelveInsight's Spinal Muscular Atrophy pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Spinal Muscular Atrophy treatment.
* The leading Spinal Muscular Atrophy Companies such as Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics , and others.
* Promising Spinal Muscular Atrophy Therapies such as Risdiplam, Nusinersen, Vesemnogene Iantuparvovec, OAV101, NMD670, GC101, Apitegromab, and others.
Stay informed about the cutting-edge advancements in Spinal Muscular Atrophy Treatments. Download for updates and be a part of the revolution in care @ Spinal Muscular Atrophy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Spinal Muscular Atrophy Emerging Drugs Profile
* Apitegromab: Scholar Rock
Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGF superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA. The US Food and Drug Administration (FDA) has granted Fast Track (FTD), Orphan Drug (ODD) and Rare Pediatric Disease (RPD) designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. Currently, it is in phase III stage of development.
* ACTX-401: Alcyone Therapeutics
ACTX-401 is an AAV9-delivered gene replacement therapy for the treatment of a rare form of Spinal Muscular Atrophy (SMA) called SMA with Respiratory Distress type 1 (SMARD1), and for Charcot-Marie-Tooth type 2S (CMT2S). SMARD1 and CMT2S are autosomal recessive genetic disorders caused by mutations in the gene that produces immunoglobulin mu-binding protein 2 (IGHMBP2) and are part of a larger family of disorders called IGHMBP2-related disorders (IRDs). ACTX-401 delivers a functional copy of the IGHMBP2 gene to patients, restoring expression of functional IGHMBP2. ACTX-401 clinical success in SMARD1 and CMT2S could lead to applicability to other IRDs in the future. Currently, it is being investigated in Phase I/II stage of development for the treatment of spinal muscular atrophy.
Learn more about Spinal Muscular Atrophy Drugs opportunities in our groundbreaking Spinal Muscular Atrophy Research and development projects @ Spinal Muscular Atrophy Unmet Needs [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Spinal muscular atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Spinal Muscular Atrophy Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Spinal Muscular Atrophy Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Spinal Muscular Atrophy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Spinal Muscular Atrophy Pipeline Report
* Coverage- Global
* Spinal Muscular Atrophy Companies- Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others.
* Spinal Muscular Atrophy Therapies- Risdiplam, Nusinersen, Vesemnogene Iantuparvovec, OAV101, NMD670, GC101, Apitegromab, and others.
* Spinal Muscular Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Spinal Muscular Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Spinal Muscular Atrophy Pipeline on our website @ Spinal Muscular Atrophy Drugs and Companies [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Executive Summary
* Spinal muscular atrophy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Spinal muscular atrophy - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Apitegromab: Scholar Rock
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Branaplam: Novartis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* ACTX 401: Alcyone Therapeutics
* Drug profiles in the detailed report....
* Inactive Products
* Spinal muscular atrophy- Unmet Needs
* Spinal muscular atrophy- Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spinal-muscular-atrophy-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spinal Muscular Atrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3705291 • Views: …
More Releases from ABNewswire
The Boulder Group Arranges Sale of Net Leased Colorado Maverik C-Store
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Maverik c-store located at 620 East Fillmore Street in Colorado Springs, Colorado for $4,950,000.
The 5,328 square-foot building is located at a signalized intersection along East Fillmore Street and experiences more than 36,000 vehicles per day. The property benefits from the proximity to Interstate 25 (149,000 VPD) and North Nevada Avenue (31,000 VPD), two major…
The Boulder Group Arranges Sale of Ground Leased Fifth Third Bank in North Carol …
The Boulder Group, a net leased investment brokerage firm completed the sale of a single tenant Fifth Third Bank located at 1121 Moncure Place in Apex, North Carolina for $2,145,000.
The Fifth Third Bank building occupies a hard corner location at Richardson Road and Core Banks Street. It is strategically situated near US 64 (42,300 VPD) and NC 540 (32,000 VPD), two main thoroughfares for the Raleigh MSA. The property is…
Power Market growing at CAGR of 4.89% | State Grid Corporation of China, Engie S …
Mordor Intelligence Report has released a report titled " Power Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2030
The global Power Market to be valued at 10.29 thousand gigawatt in 2025 and is expected to reach 15.76 thousand gigawatt CAGR of 4.89% between 2025 and 2030. Electricity demand continues to rise across regions, supported by urbanization, industrial expansion, and government-led clean energy initiatives.
The global power market [https://www.mordorintelligence.com/industry-reports/power-market?utm_source=abnewswire] trajectory reflects…
Retail Oil and Gas Logistics Market Size projected to reach USD 29.88 billion by …
Mordor Intelligence has published a new report on the retail oil and gas logistics market offering a comprehensive analysis of trends, growth drivers, and future projections.
Market Overview
According to Mordor Intelligence, the retail oil and gas logistics market [https://www.mordorintelligence.com/industry-reports/retail-oil-and-gas-logistics-market?utm_source=abnewswire] is on track for consistent expansion through the forecast period, the retail oil and gas logistics Market size is estimated at USD 24.22 billion in 2025, and is expected to reach USD…
More Releases for Spinal
Evolving Market Trends In The Spinal Fusion Devices Industry: Advancements In Sp …
The Spinal Fusion Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_
_x000D_
What Is the Expected Spinal Fusion Devices Market Size During the Forecast Period?_x000D_
Over the past few years, there has been a significant growth in the spinal fusion devices market. The market is projected…
Key Influencer in the Spinal Fusion Devices Market 2025: Rising Spinal Disorder …
What Is the Forecasted Market Size and Growth Rate for the Spinal Fusion Devices Market?
The market for spinal fusion devices has experienced significant growth in the past couple of years. Expectations are that it will rise from estimates of $7.85 billion in 2024 to approximately $8.31 billion in 2025, giving us a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this notable expansion during the historical period can…
Disposable Spinal Instrument Market: Revolutionizing Spinal Surgery with Hygiene …
Introduction
The medical device market has witnessed a surge in demand for disposable instruments, especially in areas where hygiene, precision, and efficiency are paramount. One such sector experiencing rapid growth is the disposable spinal instrument market. Spinal surgeries, being intricate and requiring high precision, have traditionally relied on reusable instruments. However, growing concerns about hygiene, infection control, and surgical efficiency have accelerated the shift toward disposable spinal instruments. These devices not…
Endoscopic Spinal Surgery Market: Minimally Invasive Solutions for Spinal Disord …
Global Endoscopic Spinal Surgery Market size was valued at US$ 667 Mn. in 2022 and the total revenue is expected to grow at a CAGR of 7.9% through 2022 to 2029, reaching nearly US$ 1137 Mn.
Endoscopic Spinal Surgery Market Overview:
Maximize Market Research is a research firm that has published a detailed analysis of the "Endoscopic Spinal Surgery Market". MMR in-depth market assessments in research reports consider significant technological advancements in…
Spinal Resilience: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
Market Outlook:
Charting Progress: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
The Acute Spinal Cord Injury Drug Pipeline Landscape sets its sights on a decade of advancements poised to redefine the trajectory of spinal resilience. This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to revolutionize the landscape of acute spinal cord injury treatment.
Market Drivers:
Neuroregeneration on the Horizon: At the forefront of the Acute Spinal Cord Injury Drug…
Spinal Laminoplasty Market - Revolutionizing spinal care with minimally invasive …
Newark, New Castle, USA: The "Spinal Laminoplasty Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Spinal Laminoplasty Market: https://www.growthplusreports.com/report/spinal-laminoplasty-market/8601
This latest report researches the industry structure, sales, revenue,…
